Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

OBJECTIVES The study assessed the relative predictive potency of neurohumoral factors in patients with advanced left ventricular (LV) dysfunction during neurohumoral blocking therapy. BACKGROUND The course of heart failure is characterized by progressive LV deterioration associated with an increase...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 38; no. 2; pp. 436 - 442
Main Authors:	Stanek, Brigitte, Frey, Bernhard, Hülsmann, Martin, Berger, Rudolf, Sturm, Barbara, Strametz-Juranek, Jeanette, Bergler-Klein, Jutta, Moser, Petra, Bojic, Anja, Hartter, Engelber, Pacher, Richard
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-08-2001 Elsevier Science
Subjects:	Adrenergic beta-Antagonists - therapeutic use Atenolol - therapeutic use Atrial Natriuretic Factor - blood Biological and medical sciences Biomarkers - blood Cardiotonic agents Cardiovascular system Double-Blind Method Endothelin-1 Endothelins - blood Female Heart Failure - blood Heart Failure - drug therapy Heart Failure - mortality Hormones - blood Humans Male Medical sciences Middle Aged Norepinephrine - blood Pharmacology. Drug treatments Placebos Prognosis Proportional Hazards Models Protein Precursors - blood Random Allocation Risk Factors Survival Rate Treatment Outcome Ventricular Dysfunction, Left - blood Ventricular Dysfunction, Left - drug therapy Ventricular Dysfunction, Left - mortality NYHA ANP N-ANP ANOVA BNP N-BNP NE LVEF LV ELISA ET Human Heart failure Brain natriuretic peptide Cardiotonic agent Prognosis Peptide hormone Cardiovascular disease Exploration Atrial natriuretic peptide Chemotherapy Natriuretic hormone Treatment Heart disease Hemodynamics Left ventricle performance Beta blocking agent
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	OBJECTIVES The study assessed the relative predictive potency of neurohumoral factors in patients with advanced left ventricular (LV) dysfunction during neurohumoral blocking therapy. BACKGROUND The course of heart failure is characterized by progressive LV deterioration associated with an increase in cardiac (natriuretic peptides) and predominantly extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels. METHODS Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients with heart failure (left ventricular ejection fraction [LVEF] <25%) receiving 40 mg enalapril/day and double-blind atenolol (50 to 100 mg/day) or placebo. After the double-blind study phase, patients were followed up to four years. Stepwise multivariate regression analyses were performed with 10 variables (age, etiology, LVEF, symptom class, atenolol/placebo, norepinephrine, big ET, log aminoterminal atrial natriuretic peptide, log aminoterminal B-type natriuretic peptide [N-BNP] and log B-type natriuretic peptide [BNP]). During the study, the last values prior to patient death were used, and in survivors the last hormone level, New York Heart Association class and LVEF at month 24 were used. RESULTS Thirty-one patients died from a cardiovascular cause during follow-up. At baseline, log BNP plasma level (x 2 = 13.9, p = 0.0002), treatment allocation (x 2 = 9.5, p = 0.002) and LVEF (x 2 = 5.6, p = 0.017) were independently related to mortality. During the study, log BNP plasma level (x 2 = 21.3, p = 0.0001) remained the strongest predictive marker, with LVEF (x 2 = 11.2, p = 0.0008) log N-BNP plasma level (x 2 = 8.9, p = 0.0027) and treatment allocation (x 2 = 6.4, p = 0.0109) providing additional independent information. CONCLUSIONS In patients with advanced LV dysfunction receiving high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy BNP and N-BNP plasma levels are both independently related to mortality. This observation highlights the importance of these hormones and implies that they will likely emerge as a very useful blood test for detection of the progression of heart failure, even in the face of neurohumoral blocking therapy.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23
ISSN:	0735-1097 1558-3597
DOI:	10.1016/S0735-1097(01)01383-3